March 19, 2020 / 12:13 PM / 9 days ago

BRIEF-TFF Pharmaceuticals Announces Phase 1 Clinical Trial Progress For Voriconazole Inhalation Powder To Treat Invasive Pulmonary Aspergillosis

March 19 (Reuters) - TFF Pharmaceuticals Inc:

* TFF PHARMACEUTICALS ANNOUNCES PHASE 1 CLINICAL TRIAL PROGRESS FOR VORICONAZOLE INHALATION POWDER TO TREAT INVASIVE PULMONARY ASPERGILLOSIS (IPA) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below